Ascent Therapeutics

Aderis Pharmaceuticals, formerly Discovery Therapeutics, develops and commercializes small molecule, receptor-specific therapeutics for the treatment of central nervous system, cardiovascular and renal diseases.

Altheus Therapeutics is developing Zoenasa Oral Controlled Release and Rectal Gel formulations as front-line therapies for the treatment of inflammatory bowel disease (IBD) with the initial focus on ulcerative colitis (UC). Zoenasa is a fixed-dose combination of the anti-inflammatory mesalamine (5-aminosalicylic acid; 5-ASA) plus an antioxidant to reduce bowel injury associated with IBD. Zoenasa is formulated as a rectal gel enema to improve efficacy in patients suffering from left-sided (distal) ulcerative colitis; and as oral formulations with an extended- and delayed-release profile for patients with proximal or extensive colitis.

Lead Pharma is a clinical-stage pharmaceutical research and development company, operating in the healthcare and pharmaceutical industry. The company's main focus is on designing and developing innovative small-molecule therapies, primarily aimed at treating autoimmune diseases and cancer. Lead Pharma primarily serves the healthcare sector, with a particular emphasis on the pharmaceutical industry. It is based in Oss, Netherlands.

Intercept Pharmaceuticals engages in the development and commercialization of novel therapeutics in the healthcare sector. Its offerings include the development and delivery of medicines for conditions such as primary biliary cholangitis and severe alcohol-associated hepatitis. The company primarily serves the healthcare industry, with a particular emphasis on liver health. It was founded in 2002 and is based in Morristown, New Jersey.

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

Founded in early 2002 by Avalon Ventures and Domain Associates, Ansata Therapeutics is developing & commercializing novel medicines that capitalize on the Company's industry- leading expertise and intellectual property in molecular transduction. Ansata has several preclinical programs under development in the oncology and neurodegenerative disease areas. The company strives to rapidly advance lead compounds from late-stage preclinical research into clinical development by leveraging its proprietary knowledge of common dermatological diseases.